Journal of the American Society of Nephrology
2008 JASN IMPACT FACTOR 7.505 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Verhagen, A. M.
Right arrow Articles by Joles, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Verhagen, A. M.
Right arrow Articles by Joles, J. A.

Journal of the American Society of Nephrology, Vol 9, 755-762, Copyright © 1998 by American Society of Nephrology


REGULAR ARTICLES

Endothelin A receptor blockade alleviates hypertension and renal lesions associated with chronic nitric oxide synthase inhibition

AM Verhagen, TJ Rabelink, B Braam, TJ Opgenorth, HJ Grone, HA Koomans and JA Joles
Department of Nephrology, University Hospital Utrecht, The Netherlands.

Unopposed actions of vasoconstrictors, such as angiotensin, play an important role in the effects of chronic nitric oxide synthase (NOS) inhibition. In this study, it is hypothesized that endothelin (ET), another important vasoconstrictor, may also play a role in the development of hypertension and renal lesions during chronic NOS inhibition. The ET(A) receptor was blocked with A-127722 during chronic NOS inhibition with Nomega-nitro-L-arginine (L-NNA), a potent NOS inhibitor without antimuscarinic action. Male Sprague Dawley rats were treated for 3 wk with L-NNA (40 mg/kg per d), L-NNA (40 mg/kg per d) + A-127722 (30 mg/kg per d), or remained untreated (control). In preliminary experiments, L-NNA (40 mg/kg per d) had been found to cause the maximum increase of systolic BP and a 35% decrease in renal NOS activity. Three weeks of L-NNA treatment resulted in a marked rise in systolic BP (240+/-4 versus control 151+/-7 mmHg; P < 0.01), proteinuria (209+/-46 versus control 27+/-3 mg/d; P < 0.01), and a fall in GFR (1.41+/-0.16 versus control 2.23+/-0.19 ml/min; P < 0.05). Renal morphology showed severe vascular injury, characterized by focal adhesion and infiltration of mononuclear cells into the intima and media of preglomerular arteries and arterioles. This was sometimes associated with necrosis of the media and partial or total obstruction of the lumen with thrombotic material. Ischemic glomeruli were also present. Tubulointerstitial damage was moderate and accompanied by an influx of monocytes and macrophages. A-127722 administered simultaneously with L-NNA completely prevented the increase in proteinuria (39+/-8 mg/d) and glomerular ischemia. Vascular injury, tubulointerstitial damage, and the increase in systolic BP (191+/-6 mmHg) were partially prevented. The protective effects of ET(A) receptor blockade suggest that ET has hemodynamic as well as nonhemodynamic effects in the cascade of events following chronic NOS inhibition.


This article has been cited by other articles:


Home page
Am. J. Physiol. Renal Physiol.Home page
Y. Kanematsu, K. Yamaguchi, H. Ohnishi, Y. Motobayashi, K. Ishizawa, Y. Izawa, K. Kawazoe, S. Kondo, S. Kagami, S. Tomita, et al.
Dietary doses of nitrite restore circulating nitric oxide level and improve renal injury in L-NAME-induced hypertensive rats
Am J Physiol Renal Physiol, November 1, 2008; 295(5): F1457 - F1462.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
S. Placier, J.-J. Boffa, J.-C. Dussaule, and C. Chatziantoniou
Reversal of renal lesions following interruption of nitric oxide synthesis inhibition in transgenic mice
Nephrol. Dial. Transplant., April 1, 2006; 21(4): 881 - 888.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
C. Chatziantoniou and J.-C. Dussaule
Insights into the mechanisms of renal fibrosis: is it possible to achieve regression?
Am J Physiol Renal Physiol, August 1, 2005; 289(2): F227 - F234.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K.-i. Aihara, H. Azuma, M. Akaike, Y. Ikeda, M. Yamashita, T. Sudo, H. Hayashi, Y. Yamada, F. Endoh, M. Fujimura, et al.
Disruption of Nuclear Vitamin D Receptor Gene Causes Enhanced Thrombogenicity in Mice
J. Biol. Chem., August 20, 2004; 279(34): 35798 - 35802.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
D.-H. Kang, T. Nakagawa, L. Feng, and R. J. Johnson
Nitric Oxide Modulates Vascular Disease in the Remnant Kidney Model
Am. J. Pathol., July 1, 2002; 161(1): 239 - 248.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
D. M. Attia, A. M. G. Verhagen, E. S. G. Stroes, E. E. van Faassen, H.-J. Grone, S. J. De Kimpe, H. A. Koomans, B. Braam, and J. A. Joles
Vitamin E Alleviates Renal Injury, but Not Hypertension, during Chronic Nitric Oxide Synthase Inhibition in Rats
J. Am. Soc. Nephrol., December 1, 2001; 12(12): 2585 - 2593.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
F. Fakhouri, S. Placier, R. Ardaillou, J.-C. Dussaule, and C. Chatziantoniou
Angiotensin II Activates Collagen Type I Gene in the Renal Cortex and Aorta of Transgenic Mice through Interaction with Endothelin and TGF-{beta}
J. Am. Soc. Nephrol., December 1, 2001; 12(12): 2701 - 2710.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
Y. Quiroz, H. Pons, K. L. Gordon, J. Rincon, M. Chavez, G. Parra, J. Herrera-Acosta, D. Gomez-Garre, R. Largo, J. Egido, et al.
Mycophenolate mofetil prevents salt-sensitive hypertension resulting from nitric oxide synthesis inhibition
Am J Physiol Renal Physiol, July 1, 2001; 281(1): F38 - F47.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
J.-J. Boffa, Ying Lu, J.-C. Dussaule, and C. Chatziantoniou
Improvements of renal lesions and function by angiotensin and endothelin receptor antagonism in nitric oxide-deficient rats
Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S211 - S216.
[Abstract] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
R. Govers and T. J. Rabelink
Cellular regulation of endothelial nitric oxide synthase
Am J Physiol Renal Physiol, February 1, 2001; 280(2): F193 - F206.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
J.-J. Boffa, P.-L. Tharaux, J.-C. Dussaule, and C. Chatziantoniou
Regression of Renal Vascular Fibrosis by Endothelin Receptor Antagonism
Hypertension, February 1, 2001; 37(2): 490 - 496.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. Matsunaga, D. C. Warltier, D. W. Weihrauch, M. Moniz, J. Tessmer, and W. M. Chilian
Ischemia-Induced Coronary Collateral Growth Is Dependent on Vascular Endothelial Growth Factor and Nitric Oxide
Circulation, December 19, 2000; 102(25): 3098 - 3103.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. F. Luscher and M. Barton
Endothelins and Endothelin Receptor Antagonists : Therapeutic Considerations for a Novel Class of Cardiovascular Drugs
Circulation, November 7, 2000; 102(19): 2434 - 2440.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
G. A. Reinhart, L. C. Preusser, T. J. Opgenorth, C. D. Wegner, and B. F. Cox
Endothelin and ETA receptors in long-term arterial pressure homeostasis in conscious nonhuman primates
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2000; 279(5): R1701 - R1706.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
A. M. G. Verhagen, D. M. A. Attia, H. A. Koomans, and J. A. Joles
Male gender increases sensitivity to proteinuria induced by mild NOS inhibition in rats: role of sex hormones
Am J Physiol Renal Physiol, October 1, 2000; 279(4): F664 - F670.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
M. BARTON, I. VOS, S. SHAW, P. BOER, L. V. D'USCIO, H.-J. GRÖNE, T. J. RABELINK, T. LATTMANN, P. MOREAU, and T. F. LÜSCHER
Dysfunctional Renal Nitric Oxide Synthase as a Determinant of Salt-Sensitive Hypertension: Mechanisms of Renal Artery EndothelialDysfunction and Role of Endothelin for Vascular Hypertrophy andGlomerulosclerosis
J. Am. Soc. Nephrol., May 1, 2000; 11(5): 835 - 845.
[Abstract] [Full Text]


Home page
HypertensionHome page
H. Berthold, A. Just, H. R. Kirchheim, and H. Ehmke
Interaction Between Nitric Oxide and Endogenous Vasoconstrictors in Control of Renal Blood Flow
Hypertension, December 1, 1999; 34(6): 1254 - 1258.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
R. G. Luke
Hypertensive nephrosclerosis: pathogenesis and prevalence : Essential hypertension is an important cause of end-stage renal disease
Nephrol. Dial. Transplant., October 1, 1999; 14(10): 2271 - 2278.
[Full Text] [PDF]


Home page
HypertensionHome page
E. L. A. Blezer, K. Nicolay, R. Goldschmeding, G. H. Jansen, H. A. Koomans, T. J. Rabelink, and J. A. Joles
Early-Onset But Not Late-Onset Endothelin-A–Receptor Blockade Can Modulate Hypertension, Cerebral Edema, and Proteinuria in Stroke-Prone Hypertensive Rats
Hypertension, January 1, 1999; 33(1): 137 - 144.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
R. Zatz and C. Baylis
Chronic Nitric Oxide Inhibition Model Six Years On
Hypertension, December 1, 1998; 32(6): 958 - 964.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
T. J Rabelink, E. S.G Stroes, K.P. Bouter, and P. Morrison
Endothelin blockers and renal protection: a new strategy to prevent end-organ damage in cardiovascular disease?
Cardiovasc Res, September 1, 1998; 39(3): 543 - 549.
[Full Text] [PDF]




HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP